Search company, investor...

Recludix Pharma

Founded Year



Series A | Alive

Total Raised


Last Raised

$60M | 2 yrs ago

About Recludix Pharma

Recludix Pharma discovers selective inhibitors of challenging protein targets. The platform approach integrates custom-generated deoxyribonucleic acid (DNA) encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. It was founded in 2019 and is based in San Diego, California.

Headquarters Location

3545 John Hopkins Circuit Suite 430

San Diego, California, 92121,

United States


Missing: Recludix Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Recludix Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Recludix Pharma News

Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 7, 2023

San Diego, California, UNITED STATES SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the virtual Oppenheimer 33rd Annual Healthcare Conference. The company’s presentation will be on Tuesday, March 14, 2023 at 12:40 p.m. Eastern Time. To access the live and archived webcast of this presentation, visit the News & Events page of the company’s website at . The archived webcast will be available for 90 days following the presentation. About Recludix Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company was founded by members of Blueprint Medicines’ founding scientific team and its management team includes industry veterans with a track record of success in the discovery, development and commercialization of multiple oncology drugs. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, inflammatory bowel disease, and others. The company is advancing three other programs to undisclosed targets that also play a significant role in both cancer and autoimmune diseases. For more information, please visit the company’s website at . Recludix Contacts:

Recludix Pharma Frequently Asked Questions (FAQ)

  • When was Recludix Pharma founded?

    Recludix Pharma was founded in 2019.

  • Where is Recludix Pharma's headquarters?

    Recludix Pharma's headquarters is located at 3545 John Hopkins Circuit, San Diego.

  • What is Recludix Pharma's latest funding round?

    Recludix Pharma's latest funding round is Series A.

  • How much did Recludix Pharma raise?

    Recludix Pharma raised a total of $60M.

  • Who are the investors of Recludix Pharma?

    Investors of Recludix Pharma include New Enterprise Associates, Westlake Village BioPartners and Access Biotechnology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.